Brilliant Pharmaceutical Achieves New Success - Betamethasone Sodium Phosphate Injection Approved, 26 Products Pass Evaluation in 2023

On July 24, the official website of the State Drug Administration (NMPA) released the latest announcement that betamethasone sodium phosphate injection, a generic drug of Chengdu Brilliant Pharmaceutical Co., Ltd. has been officially approved and deemed to have passed the evaluation. This achievement marks another significant achievement for Bett Pharmaceutical in 2023. According to statistics, since the beginning of the year, Bette Pharmaceutical and its subsidiaries have successfully passed the evaluation of the number of drugs reached 26, which fully demonstrates the company's strong research and development capabilities and market competitiveness.

Betamethasone sodium phosphate injection, as a glucocorticoid drug widely used in clinic, plays an important role in the treatment of allergic and autoimmune diseases, such as lupus erythematosus, rheumatoid arthritis, asthma and other chronic diseases. According to the data of pharmaceutical Rongyun, the sales of the drug in the national hospital market in 2023 has exceeded 100 million yuan, an increase of nearly 45%, and the market demand continues to maintain a strong trend.

In the field of generic drugs, the production approval of betamethasone sodium phosphate injection is also extremely competitive. At present, a total of 8 domestic enterprises have obtained the production approval of the drug, of which 3 enterprises, such as Chongqing Huabang Pharmaceutical, Chengdu Brilliant Pharmaceutical and Suicheng Pharmaceutical, have successfully passed the evaluation. In addition, there are 17 enterprises are actively reporting the listing of the variety, is in the review and approval stage.

In recent years, Bett Pharmaceutical has continuously committed to the enrichment and expansion of its product line, and the number of generic drug approvals has continued to hit a new high. In particular, in 2023, the company and its subsidiaries have successfully passed the evaluation of 26 drug varieties, including three important varieties with first imitation significance, such as Furosemide oral solution. These achievements not only highlight the strong strength of Brilliant Pharmaceutical in the field of research and development, but also provide more high-quality and reliable drug choices for the majority of patients.

Looking forward to the future, Bette Pharmaceutical will continue to increase investment in research and development, and continue to promote the enrichment and upgrading of product pipelines. The company is committed to providing patients with better quality and more reliable medical products, and contributing its own strength to the cause of human health.